secondary endpoint

Related by string. secondary endpoints * SECONDARY . Secon dary . Secondary : Secondary School . Secondary Schools . Secondary Offering . Secondary Education / Endpoint . Endpoints . EndPoint : Secondary endpoints include . secondary efficacy endpoints . primary efficacy endpoint * Secondary endpoints included . specified secondary endpoints . Key secondary endpoints *

Related by context. All words. (Click for frequent words.) 83 primary endpoint 81 secondary endpoints 80 primary efficacy endpoint 75 secondary efficacy endpoints 74 primary endpoints 73 secondary efficacy endpoint 70 composite endpoint 69 Secondary endpoints 69 prospectively defined 69 efficacy endpoint 69 Secondary endpoints included 68 primary efficacy endpoints 67 prespecified 66 efficacy endpoints 66 p = #.# [002] 65 clinical endpoints 65 Secondary endpoints include 65 Primary endpoints 64 demonstrated statistically significant 64 timepoint 64 free survival PFS 63 desvenlafaxine succinate 63 achieved statistical significance 63 prespecified secondary 63 cytogenetic response 63 Psoriasis Area 63 noninferiority 62 non inferiority 62 median PFS 62 Montgomery Asberg Depression 62 undetectable HCV RNA 62 morphometric vertebral fractures 62 evaluable patients 62 statistically significant improvement 62 progression TTP 62 endoscopic remission 62 Secondary efficacy endpoints 62 chlorambucil 62 Kaplan Meier analysis 62 virologic response 61 evaluable 61 Crohn Disease Activity 61 Negative Syndrome 61 complete cytogenetic 61 p = #.# [004] 61 statistical significance 61 surrogate endpoint 61 clinically meaningful improvements 61 placebo p 61 XIENCE V PROMUS Stent 60 HAMD 60 CIMZIA TM 60 ACR# response 60 ATACAND 60 P = .# 60 infarct size 60 Rating Scale MADRS 60 clinically meaningful improvement 60 mg dose 60 sustained virologic response 60 bosentan 60 CIMZIA ™ 60 nonfatal MI 60 placebo p = 60 STRIDE PD 60 statistically significant reduction 60 clinically meaningful 60 subanalysis 60 TAXUS Stent 60 ACTEMRA 60 tolvaptan 60 RE LY ® 60 SPIRIT FIRST 60 biochemical recurrence 60 placebo 60 ACR# [002] 60 SVR# 60 FOLPI 60 ACTEMRA TM 60 placebo controlled clinical 59 Free Survival PFS 59 DAS# [002] 59 elagolix 59 Unified Parkinson Disease 59 TIMI 59 CSBM 59 virological response 59 Thrombolysis 59 Scale EDSS 59 diameter stenosis 59 events MACE 59 Median progression 59 retinal thickness 59 CIMZIA TM certolizumab pegol 59 HbA1c levels 59 demonstrated clinically meaningful 59 symptomatic VTE 59 active comparator 59 mg BID 59 Randomized Evaluation 59 teriflunomide 59 mg QD 59 Expanded Disability Status 59 tumor progression TTP 59 TRITON TIMI 59 lopinavir r arm 59 achieved PASI 59 MEND CABG II 58 reinfarction 58 Major Adverse Cardiac 58 HDRS 58 XIENCE V demonstrated 58 prospective multicenter randomized 58 CR nPR 58 nab paclitaxel 58 elotuzumab 58 viral kinetic 58 tipranavir r 58 CDAI score 58 pharmacokinetic PK 58 rosuvastatin #mg 58 achieved ACR# 58 ADAS cog 58 EVEREST II 58 oxycodone CR 58 ruboxistaurin 58 achieve statistical significance 58 PANSS 58 death reinfarction 58 HAQ DI 58 exploratory endpoints 58 ipsilateral stroke 58 Events MACE 58 fondaparinux 58 eplerenone 58 undetectable HBV DNA 58 LVEF 58 pharmacodynamic 58 LEXIVA r 58 target vessel revascularization 58 IPSS 58 Phase 2b study 58 PASI scores 58 patients evaluable 58 HBeAg positive patients 58 alicaforsen enema 58 virologic failure 58 GAMMAGARD 58 thromboembolic events 58 Index CDAI 58 PRECiSE 58 neurologic progression 58 nonresponders 58 mg kg dose 58 cEVR 58 nonrandomized 58 DAPT 58 FOLFOX4 58 binary restenosis 58 periprocedural 58 PSADT 58 systemic embolism 58 CCyR 57 #mg BID [001] 57 Alzheimer Disease Assessment 57 spontaneous bowel movements 57 ADCS CGIC 57 mcg kg 57 plasma uric acid 57 metabolic parameters 57 adalimumab 57 RECIST Response Evaluation Criteria 57 apremilast 57 univariate analysis 57 annualized relapse 57 everolimus eluting stents 57 SYNTAX trial 57 TAXUS ATLAS 57 CDAI 57 lipid parameters 57 tolerability 57 APTIVUS r 57 cangrelor 57 octreotide LAR 57 pharmacokinetics PK 57 plus dexamethasone 57 treatment emergent adverse 57 tapentadol ER 57 NLX P# 57 sunitinib 57 sUA 57 evaluable subjects 57 definite stent thrombosis 57 MADRS score 57 recurrent glioblastoma multiforme 57 headache nasopharyngitis 57 myocardial infarction MI 57 mucosal healing 57 mITT population 57 abdominal pain abdominal discomfort 57 MACCE 57 #mg BID [003] 57 gout flares 57 certolizumab 57 response CCyR 57 sirolimus eluting stents 57 serum phosphorous 57 Response Evaluation Criteria 57 TAXUS Express Stent 57 TLUS 57 creatinine clearance 57 MEND CABG 57 recurrent ischemia 57 mcg QD 57 HCV RNA 57 vandetanib 57 laboratory abnormalities 57 recurrent GBM 57 serologically active patients 57 FOLFIRI 57 ADAS Cog 57 tipranavir 57 6MWD 57 BENICAR 57 ARIXTRA 57 R# #mg BID 57 complete cytogenetic response 57 ABC/3TC 57 XGEVA 56 HAM D# 56 Pharmacokinetic 56 mTSS 56 NYHA functional class 56 clodronate 56 EDEMA4 trial 56 Adalimumab 56 Scale PANSS 56 vismodegib 56 NATRECOR R 56 QTc prolongation 56 RECIST criteria 56 angiographic outcomes 56 serum phosphorus 56 HBeAg seroconversion 56 ischemic cardiomyopathy 56 tiotropium 56 nonsignificant 56 APEX AMI trial 56 #mg/day [001] 56 pharmacokinetic PK profile 56 NEVO ™ 56 IIIa inhibitor 56 paclitaxel eluting stents 56 tumor shrinkage 56 p = 56 plus methotrexate 56 irbesartan 56 glufosfamide 56 NATRECOR ® 56 BENICAR HCT 56 Acute Ischemic Stroke 56 dosage regimens 56 EDEMA3 trial 56 #mg QD [002] 56 bortezomib refractory 56 pharmacodynamic effects 56 4mg/kg 56 5-FU/LV 56 rolofylline 56 Montgomery Åsberg Depression 56 alvimopan 56 inflammatory lesions 56 #.#/#.# mmHg [001] 56 nonfatal myocardial infarction 56 Amrubicin 56 Rating Scale UPDRS 56 ticagrelor 56 sirolimus eluting stent 56 posaconazole 56 cardiovascular morbidity 56 melphalan prednisone 56 remission CR 56 liver histology 56 mcg BID 56 nausea photophobia 56 TNSS 56 DMARD 56 YMRS 56 Brief Psychiatric 56 pCR 56 pharmacodynamic PD 56 systolic BP 56 CYPHER ® Stent 56 HIV RNA 56 statistically significant 56 peginterferon 56 Tiotropium 56 Monotherapy 56 trough FEV1 56 NIH CPSI 56 ARCOXIA 56 UPDRS 56 placebo controlled 56 HbA 1c 56 serum HCV RNA 56 pain palliation 56 limiting toxicity 56 rapid virologic response 56 monotherapy 56 pegylated interferon alfa 2b 56 PSA nadir 56 SYMMETRY trial 56 prospectively stratified 56 symptom severity 56 glycated hemoglobin levels 56 HBeAg negative patients 56 DAS# CRP 56 dosing cohorts 55 docetaxel 55 edoxaban 55 International Prostate Symptom 55 Solid Tumors criteria 55 CANCIDAS 55 mg TID 55 reach statistical significance 55 MADRS 55 statistically significant p = 55 events AEs 55 rotigotine 55 dacarbazine 55 GOUT 55 neoadjuvant chemotherapy 55 briakinumab 55 comparator arm 55 adefovir 55 #mg QD [001] 55 iniparib 55 analgesic efficacy 55 alteplase 55 graft dysfunction 55 placebo controlled randomized 55 imatinib 55 administered subcutaneously 55 Sustained virologic response 55 Severity Index PASI 55 plus ribavirin 55 Nesiritide 55 Neuropsychiatric Inventory NPI 55 oral FTY# 55 ibandronate 55 mRCC 55 Pain Intensity 55 Phase Ib clinical 55 eptifibatide 55 gadolinium enhancing lesions 55 Kaplan Meier estimates 55 adjunctive placebo 55 mg/m2 dose 55 solifenacin 55 low dose cytarabine 55 randomized 55 ToGA 55 oblimersen 55 EURIDIS 55 VELCADE melphalan 55 cilostazol 55 SABCS 55 fasting plasma glucose 55 clevidipine 55 cerebrovascular events 55 BRIM2 55 etanercept 55 Timed Walk 55 HORIZONS AMI trial 55 ximelagatran 55 dose limiting toxicities 55 intermittent dosing 55 GERD symptom 55 SIMPADICO 55 lispro 55 FOLFOX6 55 proteinuria 55 IBDQ 55 myocardial infarction stroke 55 F FDG PET 55 Health Assessment Questionnaire 55 Octreolin 55 sustained virological response 55 azacitidine 55 peg interferon 55 subgroup analyzes 55 Azixa 55 activated partial thromboplastin 55 DASISION 55 HOMA IR 55 tocilizumab 55 Cmax 55 postintervention 55 detectable HCV RNA 55 postoperative mortality 55 iclaprim 55 rivaroxaban 55 MACE 55 posttransplant 55 HbA1c 55 microalbuminuria 55 EDEMA3 55 icatibant 55 severe exacerbations 55 adenoma recurrence 55 preoperatively 55 substudy 55 SBMs 55 plus gemcitabine 55 rALLy trial 55 DAS# remission 55 EBMT criteria 55 FOLFOX 55 prospective randomized controlled 55 relapsing multiple sclerosis 55 insulin detemir 55 NYHA class 55 #mg dose [003] 55 EGFR TKI 55 TACE 55 apnea hypopnea index 55 randomized blinded 55 #mg BID [002] 55 fosbretabulin 55 ancrod 55 locoregional recurrence 55 Doxil ® 55 pregabalin 55 OAB symptoms 55 riociguat 55 endpoints 55 Phase III HEAT 55 dyspnea 55 dose cohort 55 orBec 55 ENDEAVOR III 55 myocardial infarction 55 chemoradiation 55 ACR# ACR# 55 ribavirin RBV 55 Xanafide 55 nasal symptom 55 CRp 55 ENDEAVOR II 55 glomerular filtration rate 55 PRIMO CABG2 55 antiplatelet agent 55 ritonavir boosted 54 RAPAFLO R 54 PEG IFN 54 RoACTEMRA 54 mcg albinterferon alfa 2b 54 ZOLINZA 54 NYHA Class II 54 HRQoL 54 Median PFS 54 lamotrigine 54 PROMACTA 54 peginterferon alfa 2a 54 WOMAC pain 54 carotid intima media 54 lumbar spine BMD 54 mg ustekinumab 54 mycophenolate mofetil 54 RECIST 54 pertuzumab 54 tolterodine ER 54 candesartan 54 QTc 54 Target Lesion Revascularization TLR 54 HCV RESPOND 2 54 platelet reactivity 54 Cimzia TM 54 pulmonary exacerbations 54 serum HBV DNA 54 APTIVUS 54 refractory AML 54 radiographic progression 54 timepoints 54 APPRAISE 54 abciximab 54 urinary N telopeptide 54 trials RCTs 54 tirofiban 54 splenectomized patients 54 octreotide 54 pharmacokinetic parameters 54 MGd 54 randomized Phase 2b 54 Solid Tumors 54 Traficet EN 54 baseline HbA1c 54 1mg dose 54 Subgroup analysis 54 clinically relevant 54 nonmetastatic prostate cancer 54 TEAEs 54 SPIRIT III 54 glatiramer acetate 54 REYATAZ r 54 dose cohorts 54 tumor recurrence 54 Scale cognitive subscale 54 sipuleucel T 54 sirolimus 54 multicentre randomized 54 disease progression 54 randomized controlled clinical 54 Elitek 54 glycosylated hemoglobin levels 54 TAXUS 54 antipsychotic efficacy 54 MERLIN TIMI 54 SGRQ 54 fibrinolytic therapy 54 Forced Vital 54 posttreatment 54 IELT 54 PEGylated interferon beta 1a 54 ANCHOR trial 54 serum phosphate levels 54 recurrent venous thromboembolism 54 Thal Dex 54 cardiovascular hospitalization 54 CALGB # [001] 54 AGILECT R 54 Ranolazine 54 Hb A1C 54 % CI #.#-#.# [003] 54 AVADO 54 valsartan 54 serum urate 54 phase IIb clinical 54 Score TOS 54 NIHSS 54 CTEPH 54 QoL 54 tecarfarin 54 FEV1 forced expiratory 54 tolerability profile 54 nondiabetic patients 54 CSBMs 54 randomized placebo controlled 54 INCB# [001] 54 oral rivaroxaban 54 CHAMPION PLATFORM 54 antiarrhythmic drug 54 VAPRISOL 54 biochemical relapse 54 ADAGIO study 54 TDF FTC 54 gefitinib 54 EFAPROXYN 54 baminercept 54 mitoxantrone 54 hemoglobin A1c HbA1c 54 EDARBI 54 SSRI citalopram 54 ARB telmisartan 54 sumatriptan naproxen sodium 54 teduglutide 54 NNT = 54 certolizumab pegol 54 estimated glomerular filtration 54 AZILECT R 54 carotid IMT 54 Endpoints 54 urate lowering therapy 54 randomization 54 corticosteroid dose 54 chronic angina 54 log# reduction 54 aspartate aminotransferase AST 54 biologic therapy 54 echocardiographic parameters 54 LPV r 54 PCWP 54 FDA defined valvulopathy 54 fasting plasma glucose FPG 54 levosimendan 54 virologic 54 chemoradiotherapy 54 KRAS status 54 target lesion revascularization 54 achieved CCyR 54 Percutaneous Coronary Intervention 54 Phase 2a clinical 54 LEVADEX 54 neoadjuvant 54 QTcF 54 CARE HF 54 androgen deprivation 54 PROTECT II 54 recurrent VTE 54 Non inferiority 54 atheroma volume 54 ACR# responses 54 mesalamine granules 54 Phase 1b 54 REMINYL ® 54 plasma concentrations 54 unblinded 54 Pivotal Phase 54 abiraterone acetate 54 antihypertensive therapy 54 peginterferon alfa 2b 54 angiographic restenosis 54 Virologic 54 Phase 2a trial 54 orthostatic hypotension 54 receiving golimumab 54 SYNTAX 54 mcg Albuferon 54 salmeterol fluticasone 54 TNF inhibitor 54 tanespimycin 54 PEGylated anti 54 MIST II 54 EDSS 54 aflibercept 54 SPIRIVA HandiHaler 54 GnRH agonist 54 #mg/day [002] 54 mitoxantrone plus 54 esomeprazole 54 Visual Analog Scale 54 coronary stenosis 54 pegylated liposomal doxorubicin 54 randomized Phase III 54 thromboembolic 54 HCV SPRINT 53 acute coronary syndromes ACS 53 trospium 53 Ereska 53 Phase IIb clinical 53 postoperatively 53 8mg/kg 53 MoxDuo TM IR 53 intravascular hemolysis 53 segment binary restenosis 53 MADIT CRT trial 53 IBS symptoms 53 relapsed MCL 53 LMWH 53 peginterferon alfa 2a #KD 53 incontinence episodes 53 Androxal TM 53 candesartan cilexetil 53 eculizumab 53 Phase IIIb 53 statistically significant differences 53 eszopiclone 53 Main Outcome Measures 53 Global Impression 53 Phase Ib study 53 subscales 53 sinus rhythm 53 lopinavir r 53 zotarolimus eluting stent 53 concomitant medications 53 aprepitant 53 Kaplan Meier method 53 randomized double 53 ACCORD Lipid 53 multivariate Cox 53 BARACLUDE r 53 bivalirudin 53 FOLPI regimen 53 Phase 1a clinical 53 Phase 2b clinical 53 ABSORB trial 53 catheter occlusion 53 LIALDA 53 KRN# 53 RE LY trial 53 ExTRACT TIMI 53 BRIM3 53 genotypic resistance 53 pioglitazone 53 zoledronic acid 53 macrovascular 53 SCr 53 plus prednisone 53 LEXIVA 53 iloprost 53 ACR Pedi 53 placebo controlled Phase III 53 preoperative 53 calcineurin inhibitor 53 cancer mCRC 53 idraparinux 53 lanthanum carbonate 53 Fibrin Pad 53 Tolerability 53 preoperative chemotherapy 53 docetaxel chemotherapy 53 blood Phe 53 Phase IIB 53 budesonide 53 β blockers 53 histologic 53 statistically significant efficacy 53 unresectable HCC 53 NIHSS score 53 clazosentan 53 pharmacokinetics 53 serum testosterone 53 Hazard Ratio 53 neoadjuvant therapy 53 plus COPEGUS 53 peg IFN 53 randomized multicenter trial 53 CYPHER ® Sirolimus eluting 53 lymphoma CTCL 53 fallopian tube cancers 53 randomized Phase IIb 53 myocardial ischemia 53 Index CDAI score 53 hemoglobin A1c levels 53 ertapenem 53 macrovascular disease 53 COPAXONE R 53 prednisone prednisolone plus 53 TNF antagonist 53 DexaSite 53 #mg dose [001] 53 discontinuations due 53 left ventricular ejection 53 confirmed CCyR 53 CNS LS 53 PRE SURGE 53 Visual Analogue Scale VAS 53 epoetin alpha 53 insulin glargine 53 Score IPSS 53 symptomatic intracerebral hemorrhage 53 distant metastasis 53 -#.# mg dL [001] 53 perioperative complications 53 dose escalation phase 53 IRESSA 53 carboplatin paclitaxel 53 Aptivus ® 53 prognostic factors 53 53 postprocedure 53 clinically meaningful reductions 53 abacavir lamivudine 53 Microplasmin 53 Capacity FVC 53 pericardial effusion 53 pharmacodynamic endpoints 53 intravitreal injection 53 chronic thromboembolic pulmonary 53 febrile neutropenia 53 PROactive study 53 placebo dexamethasone 53 calculated creatinine clearance 53 PRIMO CABG 53 APTIVUS R 53 hemodynamically significant 53 EVIZON 53 TMC# C# 53 PREZISTA r 53 cytogenic 53 6R BH4 53 QNEXA 53 partial remissions 53 OADs 53 complete remissions 53 WOMAC 53 cinacalcet 53 pharmacokinetic profile 53 systolic function 53 Ceplene/IL-2 53 CAMMS# 53 atrasentan 53 Dasatinib 53 rosuvastatin 53 BARACLUDE ® 53 ULORIC 53 Phase IIa clinical 53 oral diclofenac 53 hypercalcemia 53 Pivotal Phase III 53 QTc intervals 53 myocardial reperfusion 53 Fludara 53 androgen suppression 53 n = 53 rimonabant #mg 53 standard chemotherapy regimen 53 liver metastases 53 EDSS scores 53 p = NS 53 PANSS total 53 lintuzumab 53 invasive aspergillosis 53 Betaferon ® 53 decitabine 53 Welchol 53 sweat chloride 53 intima media thickness 53 methotrexate monotherapy 53 anastrozole 53 ramipril 53 carotid endarterectomy CEA 53 rFVIIa 53 goserelin 53 Tavocept 53 dyspnoea 53 NSABP C 53 Darusentan 53 brivaracetam 53 Hamilton Anxiety Scale 53 experienced virologic failure 53 Restenosis 53 INCB# [003] 53 Pharmacokinetic parameters 53 Natalizumab 53 velafermin 53 Hematologic 53 Dextofisopam 53 mRS 53 IOP lowering 53 Sustained Virological Response 53 ALVESCO 53 AIR CF1 53 hip BMD 53 macrovascular events 53 enoximone 53 TAXUS Liberte Long 53 eGFR 53 undetectable viral load 53 imatinib therapy 53 pramipexole 53 Pegasys ® 53 #mg/m# [002] 53 subscale scores 53 vidofludimus 53 confidence interval CI 53 FEV1 53 covariate 53 Acute Myocardial Infarction 53 refractory NSCLC 53 Candesartan 53 prostate cancer PCa 53 corrected QT interval 53 FFNS 53 liver transplant recipients 53 moderate renal impairment 53 TAXUS VI 53 aliskiren 53 blinded randomized 53 unfractionated heparin UFH 53 alkylating agent 53 left ventricular dysfunction 53 oral ridaforolimus 53 virologic response EVR 53 randomized #:# 53 Laquinimod 53 Pred Forte 53 fosamprenavir 53 vasomotor symptoms 53 Sorafenib HCC Assessment 53 postdose 53 antiviral efficacy 53 RE LY 53 phase IIIb 53 phase IIb trial 53 phase IIa 52 glycosylated hemoglobin HbA1c 52 WOMAC scores 52 ponatinib 52 acutely decompensated congestive heart 52 NYHA Class III 52 paliperidone ER 52 CYPHER ® 52 crizotinib PF # 52 fraction LVEF 52 UPDRS motor 52 extrapyramidal symptoms 52 Randomized Study 52 CR CRu 52 Dapagliflozin 52 macroalbuminuria 52 zolmitriptan 52 RLAI 52 microvascular complications 52 p = #.# [003] 52 pegylated interferon peg IFN 52 custirsen 52 Zerenex 52 Edwards SAPIEN valve 52 ACUITY trial 52 nucleoside naive patients 52 efficacy tolerability 52 QD dosing 52 null responders 52 plus MTX 52 IRLS 52 tenecteplase 52 CLARITY study 52 elevated transaminases 52 hematologic toxicity 52 pharmacodynamics PD 52 placebo controlled clinical trials 52 endpoint 52 infliximab 52 gemcitabine Gemzar 52 CLL8 52 attain statistical significance 52 log# IU mL 52 Carotid Revascularization Endarterectomy vs. 52 EDSS score 52 PANSS scores 52 repeat paracentesis 52 fatal myocardial infarction 52 TAXUS Liberte Stent 52 LOVENOX 52 beta blocker therapy 52 NPH insulin 52 pharmacokinetic equivalence 52 locoregional disease 52 mg BID dose 52 liposomal doxorubicin 52 PreCISe study 52 metastatic HRPC 52 Abciximab 52 oral anticoagulant 52 postoperative complication 52 carotid artery stenting CAS 52 EMBLEM TM 52 safinamide 52 HbA 1c levels 52 cisplatin vinorelbine 52 CorVue ™ 52 dapagliflozin plus 52 OMNARIS HFA 52 DSMB 52 COPEGUS 52 plasma pharmacokinetics 52 Oral Fingolimod 52 placebo controlled Phase 52 IV NSCLC 52 randomized clinical 52 MIRCERA 52 degarelix 52 NMIBC 52 CombAT 52 DLTs 52 dosing cohort 52 TMC# r 52 multicenter randomized controlled 52 Cypher Stent 52 primary percutaneous coronary 52 elevated ALT 52 TYKERB 52 PEGINTRON TM 52 hypoglycemic events 52 romiplostim 52 GFT# 52 canakinumab 52 CYPHER R Stent 52 prognostic variables 52 axitinib 52 visilizumab 52 COMFORT II 52 ALND 52 maximal treadmill 52 AIM HIGH 52 prospective observational 52 docetaxel Taxotere 52 lacosamide 52 biphasic insulin aspart 52 daily Infergen 52 HeFT 52 randomized discontinuation trial 52 coronary revascularization 52 pharmacokinetic characteristics 52 statistical significance p 52 relapsed MM 52 glycoprotein IIb IIIa inhibitor 52 ongoing Phase 1b 52 randomized multicenter 52 mesalamine 52 randomized controlled 52 metastatic CRC 52 opioid induced bowel dysfunction 52 inotropic 52 Pharmacokinetics PK 52 histologically confirmed 52 upper gastrointestinal bleeding 52 entecavir

Back to home page